The study demonstrates the effectiveness of the adjuvanted RSV vaccine in people over 60 years of age.

Compilation
Study shows effectiveness of adjuvanted vaccine RSVPreF3 OA respiratory syncytial virus (RSV) in people over 60 years of age and other risk groups, including older people or people with other underlying health conditions, as presented by GSK at the congress Spanish Association of Vaccinologists (AEB).

“The results obtained in this study demonstrate the effectiveness of the RSV adjuvanted vaccine.”

“The results observed in this study demonstrate the effectiveness of adjuvanted RSV vaccine, especially in those populations that would benefit most from vaccination, as they are at greater risk of developing severe forms of disease such as adults over 70 years old And population with COPD, asthma, diabetes or heart disease“he stated Felipe Villar, Deputy Director of the Pulmonology Service at the Jiménez Díaz University Hospital, who is also one of the authors of the analysis.

The investigation found the vaccine was “sustainedly effective” for “at least three seasons” over a five-year follow-up period.

The pulmonologist explained that the results may help future evolution of the adult vaccination scheduleto improve effectiveness for those patients with chronic respiratory diseases, especially patients with RSV, whose vaccination “should be a priority“, GSK said in a statement. During the investigation, it was possible to verifysustainable efficiency» vaccines during «at least three seasons“over a five-year follow-up period.

The company conducted a study taking into account “only” direct health care costsand its purpose was to estimate the relationship between additional costs and efficiency vaccination strategies compared with non-immunization, and this relationship also improved when the indirect effect of RSV infections was taken into account.”through a social perspective.”